Tasfigo succinate is an anti-tumor drug targeting FGFR1/2/3, mainly used to treat biliary cancer patients with FGFR2 gene abnormalities. The following is an explanation from three aspects: indications, usage and dosage, and medication for special populations.

1. Approved indications

The indication for treating unresectable biliary tract cancer patients who have progressed after chemotherapy and carry FGFR2 gene fusion or rearrangement.

2. Conventional usage and dosage

The recommended dose for adults is 140mg once daily (equivalent to 4 35mg tablets), which should be taken whole and on an empty stomach. The tablets are coated with a yellow film and have the "TAS35" logo printed on the surface.

3. Principle of dose adjustment

(1) Adverse reaction management

Hyperphosphatemia at 7.1-9.0mg/dL requires discontinuation of medication until ≤ 7.0mg/dL, followed by reduction and recovery; Medication should be stopped immediately if it is ≥ 9.1mg/dL. Corneal/retinal disease grades 2-3 require discontinuation of medication until ≤ grade 1, followed by a reduction in dosage. Grade 4 requires permanent discontinuation of medication.

(2) Hematotoxicity

Grade 3 blood toxicity requires discontinuation of the drug until it reaches ≤ Grade 2, and the original dose or reduction should be restored; Level 4 requires reduction and restoration. Other grade 3 adverse reactions need to be discontinued until ≤ grade 1 before reducing dosage, and grade 4 non life-threatening abnormalities should be treated the same as grade 3.

4. Medication recommendations for special populations

(1) Pregnant women

For pregnant or potentially pregnant women, use should only be considered when there is a clear assessment that the benefits of treatment significantly outweigh the risks.

(2) Lactating women

It is recommended that lactating women avoid using this medication as it may pose a risk to the baby through milk secretion.

(3) Liver function impairment

The drug is mainly metabolized in the liver, and patients with liver dysfunction may experience an increase in blood drug concentration, so caution should be exercised when using it.

(4) Children

Clinical trials have not yet been conducted in pediatric patients, and the safety and efficacy are not yet clear.

(5) Reproductive potential population

Strict contraceptive measures should be taken, and female patients should use contraception during the medication period and within 6 days after discontinuation.